Healint, a global leader in AI-driven healthcare solutions for Central Nervous System (CNS) and Immune System conditions, and Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, have entered into a collaboration aimed at enhancing the way patients with CNS and immune conditions are managed and treated.

The partnership will capitalize on the combined capabilities of the two organizations to provide support to pharmaceutical partners aiming to deliver enhanced patient experiences through innovative digital solutions.

The collaboration aims to support the development of a new category of PSPs, DTx and studies thanks to the connectivity of Aptar’s drug delivery devices, Aptar’s SaMD and DTx Framework, coupled with Healint’s capacity to serve millions of patients in neurology for both data-capture and high-speed delivery of digital solutions to those patients and their specialist health care providers. During the AAN, the capacity to produce high precision real-world algorithms for treatment evaluation1, and predictive analytics to optimize the timing of intake of the treatment will be discussed based on Healint’s data. The companies will share how this can be deployed in a broad range of CNS conditions to bring the patients through a digital patient journey starting from Phase II and continuing up to the Digital Therapeutics augmenting the Drug’s experience.

Adam Shain, Vice President, Business Development at Aptar Digital Health, stated, “We are excited to join forces with Healint and bring our combined expertise to address the significant challenges faced by patients with CNS and Immune System conditions. Our collaboration represents a major step forward in our shared mission to improve the lives of millions of people worldwide.”

“At Healint, we are delighted by our collaboration with Aptar Digital Health as we know together we will be able to deliver the best to our clients. We are combining Aptar’s proven experience with digital patient support coupled with Healint’s 10 years of building the world leading platform for CNS. Our clients know we are the best option to bring their digital projects to life and surpass the competition’s digital initiative,” said François Cadiou, CEO and co-founder of Healint. “This will open new treatment and relief opportunities in migraine as well as numerous other chronic conditions.”